Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Aspire Biopharma Inc.

    NASDAQ: ASBP · Real-Time Price · USD
    0.53
    0.01 (1.96%)
    At close: Aug 21, 2025, 3:59 PM
    0.51
    -2.91%
    After-hours: Aug 21, 2025, 07:59 PM EDT
    1.96%
    Bid 0.5
    Market Cap 26.02M
    Revenue (ttm) n/a
    Net Income (ttm) -30.13M
    EPS (ttm) -0.61
    PE Ratio (ttm) -0.86
    Forward PE n/a
    Analyst n/a
    Ask 0.54
    Volume 47,165,485
    Avg. Volume (20D) 22,769,148
    Open 0.59
    Previous Close 0.52
    Day's Range 0.49 - 0.65
    52-Week Range 0.21 - 15.80
    Beta 0.80

    About ASBP

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ASBP
    Website n/a
    Full Company Profile
    4 days ago
    +64.35%
    Aspire Biopharma Holdings shares are trading highe... Unlock content with Pro Subscription
    1 month ago
    +4.12%
    Aspire Biopharma Holdings shares are trading higher after the company announced consumer feedback for BUZZ BOMB.
    news image

    4 days ago · accessnewswire.com

    Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

    According to the NIH , Acute myocardial infarction (AMI) is a major cause of death, affecting nearly 3 million Americans each year and resulting in over a million deaths Trial demonstrates dramaticall...

    news image

    1 week ago · accessnewswire.com

    Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

    ESTERO, FL / ACCESS Newswire / August 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug and supplement delivery tec...

    news image

    1 week ago · accessnewswire.com

    Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

    BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout to help athletes and fitness enthusiasts maximize their performance potential 30,000 BUZZ BOMB™ s...

    news image

    3 weeks ago · accessnewswire.com

    Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

    First sublingual pre-workout single-serving supplement that delivers 50mg of caffeine rapidly to the body, is now available to order via Aspire's new direct-to-consumer shopping experience ESTERO, FL ...

    news image

    3 weeks ago · accessnewswire.com

    Aspire Biopharma Holdings, Inc. Announces CEO Transition

    Kraig Higginson, Current Chairman of the Board, Appointed Interim CEO ESTERO, FL / ACCESS Newswire / July 30, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), develope...

    news image

    1 month ago · accessnewswire.com

    Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

    Sublingual nano technology delivers 50mg of caffeine rapidly to the body, bringing its unique benefits to the pre-workout market ESTERO, FL / ACCESS Newswire / July 22, 2025 / Aspire Biopharma Holding...

    news image

    1 month ago · accessnewswire.com

    Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

    Early positive consumer testimonials from initial Company product sampling Sublingual nano technology delivers caffeine rapidly to the bloodstream, bringing its unique benefits to the pre-workout mark...

    news image

    1 month ago · accessnewswire.com

    Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

    Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025 ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "C...

    news image

    2 months ago · accessnewswire.com

    Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

    Michael Howe - who currently serves as an Independent Board Member - to assume CEO role on June 10, 2025 Michael's career spans nationally recognized brands such as MinuteClinic, Procter & Gamble, Pep...

    news image

    2 months ago · accessnewswire.com

    Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

    Sublingual nano technology delivers caffeine rapidly to the blood stream, bringing its unique disruptive benefits to the Pre-workout market Initial production has commenced with six flavor options Exp...

    Add to Watchlist